Summary

Location
at San Francisco, California and other locations
Dates
study started
study ends around
Principal Investigator
by Vasanth Vedantham, MD, PhD
Headshot of Vasanth Vedantham
Vasanth Vedantham

Description

Summary

Calcium Release Deficiency Syndrome (CRDS) is a newly discovered genetic arrhythmia syndrome that confers a risk of life-threatening arrhythmias secondary to RYR2 loss-of-function. The International CRDS registry has been designed to facilitate large-scale evaluation of CRDS, including its phenotypic spectrum, approaches to risk stratification, and optimal treatment strategies.

Official Title

International Calcium Release Deficiency Syndrome Registry

Details

Calcium Release Deficiency Syndrome (CRDS) is a recently discovered inherited arrhythmia syndrome that predisposes to malignant ventricular arrhythmias and sudden cardiac death (SCD). The underlying genetic culprit of CRDS is RYR2, which encodes the cardiac ryanodine receptor. In contrast to Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), which stems from pathogenic RYR2 gain-of-function, CRDS manifests secondary to RyR2 loss-of-function. Enrolment into the CRDS registry requires that the putative disease causing RYR2 variant is confirmed to result in a loss-of-function on in vitro functional analysis. Individuals possessing an RYR2 truncating variant or large copy number variant will be eligible for enrolment into a second registry arm. Patients with a suspected CRDS diagnosis whose RYR2 variant is found not to impact function will be entered into a control arm of the registry.

Given its recent discovery, our understanding of CRDS remains in its infancy. The International CRDS registry has been designed to facilitate evaluation of large numbers of CRDS patients and enable robust insights to hopefully improve management of affected patients and families.

Keywords

Calcium Release Deficiency Syndrome, Syndrome, CRDS, Carrier of a non-functional RYR2 rare variant

Eligibility

CRDS Cohort

Inclusion Criterion:

  • Presence of a rare* RYR2 variant that is characterized to be loss-of-function based on in vitro testing#

RYR2 Truncating and Large CNV Cohort

Inclusion Criterion:

  • Presence of a rare* RYR2 truncating variant and/or large copy number variant involving the RYR2 gene.

Carriers of a Non-Functional RYR2 variant

Inclusion Criterion:

  • Presence of a rare* RYR2 variant that is characterized to be neither loss- nor gain-of-function based on in vitro testing#

*rare defined as gnomAD prevalence < 0.1%

RYR2 in vitro functional testing will be performed in the laboratory of Dr. Wayne Chen

(University of Calgary)

Locations

  • University of California accepting new patients
    San Francisco California 94143 United States
  • London Health Sciences Centre - University Hospital accepting new patients
    London Ontario N6A 5A5 Canada

Lead Scientist at UCSF

  • Vasanth Vedantham, MD, PhD
    Dr. Vedantham is cardiologist and clinical cardiac electrophysiologist, specializing in treatment of heart rhythm disorders using catheter ablation, pacemaker and defibrillator implantation, and antiarrhythmic medications.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Population Health Research Institute
ID
NCT06508164
Study Type
Observational [Patient Registry]
Participants
Expecting 500 study participants
Last Updated